Émilie Orlhac

Special golf experiences up for bid as Quebec’s golf community tees off to support ALS Quebec MONTRÉAL, August 5th, 2025 — One year after its impactful launch, United on the Greens to End ALS is returning to Quebec this year. Uniting Quebec’s golf community in support of families affected by amyotrophic lateral sclerosis (ALS), the province-wide fundraising initiative invites golf...

Health Canada has agreed to review a New Drug Submission (NDS) for Tofersen, for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. A regulatory decision on the New Drug Submission is expected in early 2025. If approved, this therapy will become the first treatment in Canada to target a genetic cause of ALS. Read the...

Today, Amylyx announced that their Phase 3 PHOENIX trial, a global, 48-week, randomized, placebo-controlled study of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine; also known as ALBRIOZA) in people living with ALS, did not meet its prespecified primary or secondary endpoints. It's understandable if this outcome has left us all feeling disheartened and discouraged. Now, more than ever,...